Pintor Luis, Baillès Eva, Valldeoriola Francesc, Tolosa Eduard, Martí María J, de Pablo Joan
Servicio de Psiquiatría, Instituto Clínico de Neurociencias, Hospital Clínico de Barcelona, 08036 Barcelona, Spain.
Gen Hosp Psychiatry. 2006 Jan-Feb;28(1):59-64. doi: 10.1016/j.genhosppsych.2005.07.005.
The aim of this study is to evaluate response to reboxetine in a 4-month follow-up study on depression in Parkinson's disease (PD), and to assess its tolerability profile.
A prospective 4-month follow-up study was performed in 17 PD patients with a major depressive episode. The intensity of depressive symptoms was evaluated mainly with the Hamilton Rating Scale for Depression (HAM-D), and PD was assessed with the Unified Parkinson Disease Rating Scale (UPDRS).
Reboxetine causes a progressive decrease in depressive symptoms in PD patients; the initial score of 16.76 (2.68) on HAM-D decreased to 5.85 (2.42) at 4 months (P < .002). Mean UPDRS scores did not show a statistically significant increase: 18.18 (2.6) at the beginning and 18.25 (2.4) at the end of the follow-up period (P = .8).
Reboxetine, as first choice treatment for major depressive episodes in PD patients, seems to be effective in progressively improving depressive symptoms over the first 4 months of treatment until complete remission. Reboxetine does not seem to increase PD symptoms, whereas patients' quality of life improves.
本研究旨在评估瑞波西汀在帕金森病（PD）抑郁患者4个月随访研究中的疗效，并评估其耐受性。
对17例伴有重度抑郁发作的PD患者进行了为期4个月的前瞻性随访研究。主要采用汉密尔顿抑郁量表（HAM-D）评估抑郁症状的严重程度，采用统一帕金森病评定量表（UPDRS）评估PD病情。
瑞波西汀可使PD患者的抑郁症状逐渐减轻；HAM-D初始评分为16.76（2.68），4个月时降至5.85（2.42）（P <.002）。UPDRS平均评分无统计学显著升高：随访开始时为18.18（2.6），结束时为18.25（2.4）（P =.8）。
作为PD患者重度抑郁发作的首选治疗药物，瑞波西汀在治疗的前4个月似乎能有效逐步改善抑郁症状直至完全缓解。瑞波西汀似乎不会加重PD症状，同时可改善患者的生活质量。
